Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus CANDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus CANDEX.
BREO ELLIPTA vs CANDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Adults: 150 mg orally once daily
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life is 20-30 hours (mean 24 hours) in adults; prolonged in hepatic impairment (up to 50 hours) and requires dose adjustment.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Primarily hepatic metabolism via CYP2C9, with <1% excreted unchanged in urine. Approximately 70-80% eliminated in feces as metabolites, 20-30% in urine as metabolites.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Topical Antifungal and Corticosteroid